Shattuck Labs, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.35) Per Share (NASDAQ:STTK)

Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2024 earnings per share estimates for shares of Shattuck Labs in a research note issued on Tuesday, October 1st. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.35) for the quarter, up from their prior forecast of ($0.46). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Shattuck Labs' current full-year earnings is ($1.72) per share. HC Wainwright also issued estimates for Shattuck Labs' Q4 2024 earnings at ($0.27) EPS, FY2024 earnings at ($1.41) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.66) EPS, FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.91) EPS.

A number of other equities research analysts also recently issued reports on the stock. Needham & Company LLC downgraded shares of Shattuck Labs from a "buy" rating to a "hold" rating and set a $8.00 price target on the stock. in a research note on Wednesday. BTIG Research cut Shattuck Labs from a "buy" rating to a "neutral" rating in a research report on Monday, June 17th. Finally, Citigroup lowered Shattuck Labs from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $8.00 to $2.00 in a report on Wednesday.

Shattuck Labs Price Performance

Shares of STTK stock traded up $0.03 during trading on Thursday, hitting $1.28. 1,503,063 shares of the stock traded hands, compared to its average volume of 437,639. The firm's fifty day moving average price is $3.43 and its 200-day moving average price is $6.01. The firm has a market capitalization of $60.87 million, a P/E ratio of -0.66 and a beta of 1.72. Shattuck Labs has a 52-week low of $1.15 and a 52-week high of $11.76.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01). The firm had revenue of $1.61 million for the quarter, compared to analysts' expectations of $0.50 million. Shattuck Labs had a negative return on equity of 68.65% and a negative net margin of 2,067.99%. The company's revenue for the quarter was up 704.5% compared to the same quarter last year.

Hedge Funds Weigh In On Shattuck Labs

A number of large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its stake in shares of Shattuck Labs by 209.7% in the second quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company's stock valued at $857,000 after purchasing an additional 150,340 shares during the period. Vanguard Group Inc. boosted its stake in Shattuck Labs by 38.2% in the 1st quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company's stock worth $16,270,000 after buying an additional 502,860 shares during the last quarter. Virtu Financial LLC acquired a new position in Shattuck Labs during the first quarter worth approximately $113,000. Acadian Asset Management LLC purchased a new position in shares of Shattuck Labs in the 2nd quarter worth $170,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Shattuck Labs in the 1st quarter valued at about $174,000. Hedge funds and other institutional investors own 58.74% of the company's stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.